European Pharmaceutical Review

DECEMBER 14, 2022

and Merck have announced that a Phase IIb trial ( NCT03897881 ) of a personalised mRNA cancer vaccine (mRNA-4157/V940), in combination with KEYTRUDA ® , Merck’s anti-PD-1 therapy, demonstrated the first randomised evidence that a personalised neoantigen approach may be beneficial in treating melanoma. Moderna, Inc.

Vaccines 116

Vaccines Immunization 116

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. This is an additional ingredient designed to trigger a stronger immune response.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

MAY 10, 2021

A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the Pfizer/BioNTech Comirnaty shot. . It is also asking for similar data from Moderna, which manufacture a COVID-19 vaccine that like Comirnaty is based on mRNA.

Vaccines 122

Vaccines Labelling Immunization 122

European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. Adverse events observed with mRNA-4157 in KEYNOTE-942 remain consistent with those previously reported.

Vaccines 115

Vaccines Research Laboratories Immunization 115

European Pharmaceutical Review

OCTOBER 21, 2022

GSK announced Shingrix (Zoster Vaccine Recombinant, Adjuvanted), the first approved shingles vaccine to combine a non-live antigen with a GSK-made adjuvant, can prevent shingles (herpes zoster) for at least decade. An interim analysis conducted over more than four years of long-term follow-up (LTFU) showed vaccine efficacy was 81.6

Vaccines 105

Vaccines Immunization 105

pharmaphorum

FEBRUARY 8, 2021

China’s national regulator has approved Sinovac Biotech’s COVID-19 vaccine for use by the general public. This is the second vaccine approved by China’s National Medical Products Administration (NMPA). Both of the vaccines, along with another experimental vaccine from Sinopharm, have been used in China’s vaccination programme.

Vaccines 90

Vaccines Immunization 90

pharmaphorum

MARCH 18, 2021

An EMA advisory committee’s review of AstraZeneca’s COVID-19 has concluded that there is no increase in the overall risk of blood clots with this vaccine. And because the vaccine is effective in preventing COVID-19 disease – which in itself is a cause of blood clots – it “likely reduces the risk of thrombotic events overall.”.

Vaccines 105

Vaccines Immunization 105

European Pharmaceutical Review

AUGUST 30, 2022

It has highlighted the value of cutting-edge technologies, such as messenger RNA (mRNA) vaccines, and reinforced the industry’s understanding of the power of collaboration, including with contract partners such as contract development and manufacturing organisations (CDMOs). The rise of the nasal vaccine route.

Vaccines 119

Vaccines Immunization 119

pharmaphorum

APRIL 30, 2021

The NHS app could be used a kind of vaccine passport, according to UK government sources, although it is unclear how far the project has progressed. . NHS England’s app is connected to GP services in England and linked to personal health data and as such could be used to show a person’s vaccine status before travelling.

Vaccines 93

Vaccines Immunization 93

European Pharmaceutical Review

AUGUST 3, 2022

The COVID-19 pandemic has demonstrated the need for an improved vaccine approach to temper the serious threat of constantly mutating viruses, such as influenza and coronaviruses, on global health. These spontaneous mutation events are quite common and often do not lead to an improved version of the pathogen.

Vaccines 95

Vaccines Immunization 95

Fierce Pharma

JUNE 29, 2023

While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. | By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday.

Vaccines 77

Vaccines Immunization 77

Pharmacy Times

SEPTEMBER 12, 2024

Programs can take several forms, including on-site clinics, voucher programs, and in-store events

Immunization 56

Immunization Vaccines 56

pharmaphorum

JULY 6, 2021

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. Millions of tests for COVID-19 are taken worldwide every day, as they become an increasingly important tool for our return to normality. ” . .

Immunization 111

Immunization Vaccines 111

Pharmaceutical Technology

MARCH 31, 2023

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccines 110

Vaccines Immunization 110

Hospital Pharmacy Europe

DECEMBER 14, 2022

mRNA-4157/V940 which represents a personalised cancer vaccine has been found effective when combined with pembrolizumab in advanced melanoma. mRNA-4157/V940 is designed to stimulate an immune response by generating a specific T cell action based on the unique mutational signature of a patient’s tumour.

Vaccines 98

Vaccines Immunization Hospitals 98

pharmaphorum

MARCH 3, 2021

Novavax hopes its COVID-19 vaccine could be filed in the US in the second quarter, following a potential approval from the UK regulator in the coming weeks. Novavax’s vaccine is a sequence of protein engineered from the genetic sequence of the SARS-CoV-2 virus that mimics the “Spike” protein found on the pathogen’s surface.

FDA 130

FDA Vaccines Immunization 130

pharmaphorum

NOVEMBER 17, 2020

Pfizer has begun a pilot delivery programme in the US for its experimental COVID-19 vaccine, as the company seeks to overcome logistical challenges caused by its ultra-cold storage requirements. The vaccine developed in partnership with Germany’s BioNTech has been shown to be 90% effective in clinical trials.

Vaccines 77

Vaccines Immunization FDA 77

pharmaphorum

FEBRUARY 18, 2021

The aim of the study is to find the smallest amount of SARS-CoV-2 that is needed to cause an infection, see how the immune system reacts to the virus, and to assist in the development of new treatments and vaccines. The study was first announced last year in a media briefing at the Wellcome Trust in London.

Vaccines 118

Vaccines Immunization 118

pharmaphorum

APRIL 6, 2021

People in the UK will start receiving doses of Moderna’s COVID-19 vaccine in around two weeks’ time, according to vaccines minister Nadhim Zahawi. Moderna’s vaccine is around 94% effective at preventing the disease, in line with the results seen from the Pfizer/BioNTech shot, which is also based around mRNA technology.

Vaccines 80

Vaccines Immunization 80

European Pharmaceutical Review

SEPTEMBER 4, 2023

Maciej Adamczyk and Monika Pyzio-Michalik, DBS Law Firm EVENT PREVIEW Modern methods in microbiology and analytics PharmaLab Congress DRUG DELIVERY Dry powder delivery to the lungs Jnanadeva Bhat, ACG EVENT PREVIEW CPHI Barcelona 2023: what to expect Featuring company profiles from BioSpectra, Lonza and Ajinomoto VACCINE DEVELOPMENT The imperative (..)

Packaging 97

Packaging Vaccines Immunization 97

pharmaphorum

MARCH 17, 2021

At the start of the pandemic GlaxoSmithKline made its vaccine booster tech available looking for collaborations with other vaccine developers – but GSK has been lagging behind rivals like Pfizer and AstraZeneca after its big tie-up with Sanofi hit technical troubles. micrograms of the vaccine are administered 21 days apart.

Vaccines 105

Vaccines Immunization FDA 105

The Checkup by Singlecare

JUNE 7, 2024

This rash-causing virus is certainly prevalent, but it’s also avoidable thanks to immunizations like Shingrix. Millions of people have already received at least one dose of this shingles vaccine—but does it actually work? Essentially, once the immune system is familiar with the virus, it will know how to fight it.

Immunization 96

Immunization Vaccines Dosage FDA 96

pharmaphorum

DECEMBER 21, 2020

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccines 111

Vaccines Immunization 111

pharmaphorum

FEBRUARY 10, 2021

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

Immunization 133

Immunization Vaccines 133

Hospital Pharmacy Europe

OCTOBER 2, 2024

Pharmacist Dr João Gonçalves PhD considers the real-world evidence of a recent study demonstrating the feasibility and efficacy of a personalised peptide vaccine for glioblastoma – one of the most malignant primary brain tumours in adults. The median overall survival (OS) for the entire cohort was 31.9

Vaccines 52

Vaccines Immunization Chemotherapy Hospitals 52

Digital Pharmacist

JANUARY 16, 2023

From cancer prevention to diabetes awareness, these events help bring communities together. World Immunization Week: April 24-30. National Immunization Awareness Month. National Influenza Vaccination Week: December 6-12. Also, don’t forget to promote these awareness events on your website and at your pharmacy.

Immunization 98

Immunization Vaccines Communication Hospitals 98

pharmaphorum

DECEMBER 7, 2020

China’s Sinovac has raised $515 million to increase its distribution and production capacity as clinical development of its potential coronavirus vaccine nears conclusion. Sinovac has a coronavirus vaccine in late-stage development, which is undergoing large-scale trials in Brazil, Pakistan, Indonesia and Chile.

Vaccines 59

Vaccines Immunization 59

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease.

Vaccines 59

Vaccines Adverse Reactions Immunization 59

pharmaphorum

JANUARY 25, 2022

Pfizer and partner BioNTech have started their clinical trial of a new version of their COVID-19 vaccine that has been specifically designed to protect against the Omicron variant. Feature image copyright BioNTech SE 2020, all rights reserved.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

FEBRUARY 25, 2021

Pfizer may have been making headlines with the COVID vaccine it developed with BioNTech, but it’s not the only infectious disease the big pharma is targeting. In a statement, Pfizer said the FDA has granted a fast review for TicoVac tick-borne encephalitis (TBE) vaccine, to prevent the disease in individuals one year of age or older.

FDA 66

FDA Vaccines Immunization 66

pharmaphorum

JANUARY 8, 2021

As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

pharmaphorum

JANUARY 8, 2021

As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford/AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

The Checkup by Singlecare

APRIL 6, 2023

Vaccines have been an essential part of protecting public health for decades. However, despite the overwhelming evidence for their effectiveness and safety, there has been an increasing trend of vaccine hesitancy in recent years. What is vaccine hesitancy? Are there any long-term risks with vaccines?

Vaccines 52

Vaccines Immunization Communication Pharmaceutical Companies 52

Pharmaceutical Technology

JULY 29, 2022

Furthermore, a 91% and 100% cystectomy avoidance rate and bladder cancer overall survival, respectively, were observed at 24 months without any serious adverse events (SAE). In January, ImmunityBio and Amyris have concluded a joint venture (JV) agreement announced previously to accelerate the marketing of a Covid-19 vaccine.

FDA 105

FDA Labelling Immunization Vaccines 105

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Vaccines 52

Vaccines Immunization Communication 52

European Pharmaceutical Review

DECEMBER 19, 2022

Treatment and care of patients with high-risk NMIBC, including those with CIS often involves removing the tumour and the use of the BCG vaccine to reduce the risk that the cancer will recur. The FDA stated that individuals who are immunosuppressed, or immune-deficient should not come into contact with Adstiladrin.

FDA 110

FDA Adverse Reactions Immunization Vaccines 110

The Checkup by Singlecare

NOVEMBER 30, 2023

In the event of an acetaminophen interaction with concerns of acute toxicity, be it an accidental or intentional overdose, contact the national poison control hotline at 800-222-1222 to be connected to a poison control center in your area. However, after vaccine administration, ACIP recommends use for fever treatment and local pain.

Immunization 98

Immunization Vaccines FDA Labelling 98